RNA Interference CD147 Expression In Human Gastric Cancer Cell Line SGC7901 Proliferation And Invasion And Related Signaling Pathways

Gastric cancer is the fourth most common cancer worldwide, and it is the second most common cause of cancer death. Despite much research, we do not yet have drugs adequate for treating gastric cancer. A better understanding of the molecular mechanisms driving gastric tumorigenesis is crucial and will provide enormous benefits in developing new and effective therapeutic treatments for gastric cancer.CD147is a heavily glycosylated type I transmembrane glycoprotein that belongs to the Ig superfamily. CD147has been implicated in numerous physiological and pathological activities. It is usually expressed at low levels in most normal tissues, but is highly upregulated during various cancer progression. CD147induces several MMPs in stromal fibroblasts and endothelialcells as well as in tumour cells themselves to promote tumor growth, invasion, metastasis.In this study, we investigate the possible role of CD147in the progression of gastric cancer by using RNA interference (RNAi) technology. Short hairpin RNA (shRNA) expression vectors targeting CD147were constructed to silence CD147, and the expression of CD147was monitored by quantitative realtime RT-PCR and Western blot. Cell proliferation, the activities of MMP-2and MMP-9, the invasive potential of SGC7901cells were determined by MTT, gelatin zymography, Matrigel invasion assay and MTT, respectively. The phosphorylation and non-phosphorylation of the mitogen-activated protein kinases ERK1/2, P38and JNK were examined by Western blot. Additionally, the ERK1/2inhibitor U0126were used to confirm the signaling pathway involved in CD147-mediated SGC7901progression.The results revealed that CD147silencing inhibited the proliferation and invasion of SGC7901cells, and down-regulated the activities of MMP-2and MMP-9and the phosphorylation of the ERK1/2in SGC7901cells. ERK1/2inhibitor U0126decreased the proliferation, and invasion of SGC7901cells, and down-regulated the MMP-2and MMP-9activities. These results suggest that ERK1/2pathway involves in CD147-mediated gastric cancer growth and invasion. These findings further highlight the importance of CD147in cancer progression, indicating that CD147would be an attractive therapeutic target for gastric cancer.